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Abstract
Background: Cardiovascular disease accounts for at least 85 percent of deaths for those patients
with type 2 diabetes mellitus (T2DM). Additionally, 75 percent of these deaths are due to ischemic
heart disease.
Hypothesis: Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia
a late manifestation? The role of NOS, NO, and redox stress.
Testing of the hypothesis: The vulnerable three arms of the eNOS reaction responsible for the
generation of eNO is discussed in relation to the hypothesis: (1). The L-arginine substrate. (2). The
eNOS enzyme. (3). The BH4 cofactor.
Implications of the hypothesis: If we view T2DM as a vascular disease initially with a later
manifestation of hyperglycemia, we may be able to better understand and modify the multiple
toxicities associated with insulin resistance, metabolic syndrome, prediabetes, overt T2DM, and
accelerated atherosclerosis (atheroscleropathy). The importance of endothelial nitric oxide
synthase, endothelial nitric oxide, tetrahydrobiopterin (BH4), L-arginine, and redox stress are
discussed in relation to endothelial cell dysfunction and the development and progression of
atheroscleropathy and T2DM. In addition to the standard therapies to restore endothelial cell
dysfunction and stabilization of vulnerable atherosclerotic plaques, this article will discuss the
importance of folic acid (5MTHF) supplementation in this complex devastating disease process.
Atheroscleropathy and hyperglycemia could be early and late manifestations, respectively, in the 
natural progressive history of T2DM.
Background
The historical discovery of the enzyme family nitric oxide
synthases (NOS) in 1989 is relatively recent and we now
know there are three distinct isoforms of NOS: neural
NOS-1 (nNOS); inducible NOS-2 (iNOS); and endotheli-
al NOS-3 (eNOS). These three isoforms were discovered
in the above order from 1991–1994 [1]. eNOS, the rate
limiting enzyme responsible for the production of en-
dothelial derived nitric oxide (eNO) was sequenced and
cloned in 1992 [2,3]. Each NOS enzyme has its own
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unique amino acid structure sharing some 50 percent ho-
mology indicating a common ancestral background. Ad-
ditionally, each NOS isoform is transcribed from a
separate gene (table 1).
Nitric oxide, voted the molecule of the year by Science
Magazine in 1992 [4] has been shown to be an extremely
important signaling molecule in the cardiovascular sys-
tem and in 1998 Furchgott RF, Ignarro LJ, and Murad F.
were awarded the Nobel Prize in Medicine and Physiology
"for their discoveries concerning nitric oxide as a signaling
molecule in the cardiovascular system" (tables 2,3).
This relatively brief and recent history of NOS and NO is
in contrast to the ancient history of atherosclerosis which
dates to the time of the Egyptians. The theories of athero-
sclerosis are legion and the atherosclerologists of today
have a proud history upon which to build for the future
[5].
The endothelial cell, such a central player, responsible for
remodeling of the arterial vessel wall in atherosclerosis
(intimopathy) and responsible for the synthesis of eNOS
and subsequent eNO production will be discussed and re-
lated to the accelerated atherosclerosis (atheroscleropa-
thy) associated with type 2 diabetes mellitus (T2DM)
[5,8–11].
This review will discuss dysfunction of the eNOS enzyme
and its potential to uncouple, resulting in the endothelial
cell becoming a net producer of damaging superoxide
(O2') instead of the protective eNO (tables 4,5) [6]. The
lack of eNO from the endothelial cell is related to the de-
velopment of atheroscleropathy and is related to the un-
derproduction and / or the excessive consumption of eNO
Table 1: Comparisons of the human NOS enzymes
nNOS NOS-1 Chromosome 12 Amino acids 
1434 aa 161 kDa
high Ca++ 
requirement
iNOS NOS-2 Chromosome 17 Amino acids 
1153 aa 131 kDa
low Ca++ 
requirement
eNOS NOS-3 Chromosome 7 Amino acids 
1203 aa 133 kDa
high Ca++ 
requirement
Table 2: The positve protective effects of eNOS
1. Promotes vasodilatation of vascular smooth muscle.
2. Counteracts smooth muscle cell proliferation.
3. Decreases platelet adhesiveness.
4. Decreases adhesiveness of the endothelial layer to WBCs 
"Teflon effect".
5. Anti-inflammatory.
6. Anti-oxidant. It scavenges reactive oxygen species, locally. Acts 
as a chain – breaking antioxidant to scavenge ROS.
7. Anti-fibrotic. When NO is normal or elevated MMPs are low 
and conversely if NO is low MMPs are elevated and active.
8. NO has diverse anti-atherosclerotic actions on the arterial ves-
sel wall: including antioxidant effects by direct scavenging of ROS 
– RNS acting as chain breaking antioxidants.
Table 3: Janus – faced properties of NO
GOOD BAD
eNO, nNO iNO *
Chromosomes 7,12 Chromosome 17
Duration: Seconds to minutes Duration: Hours to days
Signaling molecule. Killer molecule.
Regulated: small bursts Unregulated: larger bursts and 
longer duration
Cytoprotective Cytotoxic
*In host defense mechanisms iNO does just what we want it to, i.e. it 
kills invading organisms. Inducible NO can also be thought of as inflam-
matory NO. Paradoxically, in both acute and chronic inflammatory 
states iNO also kills the native hosts cells in the immediate surround-
ing area.
Table 4: Lab – garbage acronym
Factors related to eNOS dysfunction with decreased NO. factors 
known to uncouple the eNOS enzyme.
L – Lipids LDL – Cholesterol elevated both native and oxidized. Ele-
vated Triglycerides of metabolic syndrome. Decreases or impairs 
dimethylarginine dimethylaminohydrolase (DDAH). Decline in DDAH 
activity. Increase in ADMA activity.
A – Arginine (L-arginine) decreased or impaired: By competitive inter-
action with ADMA (asymmetric dimethylarginine) an endogenous 
nitric oxide synthase inhibitor. Elevated in proatherogenic conditions. 
ACE, Ang II, endothelin, hypertension, insulin resistance, prediabetes, 
T2DM, and hyperhomocysteinemia.
B – BH4 Decreased or impaired Folic acid regeneration of the cofac-
tor BH4 i.e. BH2 → BH4 with 5 methyl tetrahydrofolate (5-MTHF) 
active form of folic acid.
G – Glucose elevation. T2DM. DDAH effect increasing ADMA similar 
to lipids and elevated homocysteine.
A – Arginine (L-arginine) decreased or impaired: By nitrosylation 
(nitroarginine). By ONOO' peroxynitrite similar to nitrosylation of 
tyrosine (nitrotyrosine).
R – ROS reactive oxygen species. Specifically O2' and ONOO' 
Decline in DDAH activity results in increased ADMA.
B – BH4 decreased or impaired. BH4 oxidized to BH2. Loss of a natu-
rally occurring antioxidant with diminished ROS scavenging capability.
A – ADMA Homocysteine impairs DDAH enzyme and increases 
ADMA.
G – Glucose elevated – glycated eNOS.
E – Endothelial NOS enzyme decreased and or dysfunctional. Gene 
polymorphism Glu298 → Asp, additional unidentified gene polymor-
phisms, CRP causing marked down regulation of eNOS mRNA and 
protein expression, eNOS enzyme glycation. Last but most impor-
tantly . . . ......
eNOS enzyme UNCOUPLINGCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/2
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by redox stress. The uncoupling of this complex enzyme
will aid in the understanding of the development of
atheroscleropathy and the role of oxidative and reductive
stress (redox stress) in patients with T2DM [7,8].
Definitions
It is important to set forth the authors' working defini-
tions before proceeding with this review.
ATHEROSCLEROSIS is a systemic dysfunctional en-
dothelial, focal occurring, chronic inflammatory, fibro-
prolifertive, angiogenic, prothrombotic, multifactorial
disease of the arterial intima caused by the retention of
modified low density lipoproteins, hemodynamic stress,
and accelerated by redox stress [5,8–11].
ATHEROSCLEROPATHY: The term used to describe the
unique accelerated atherosclerosis observed in and associ-
ated with metabolic syndrome, insulin resistance,
prediabetes, and overt T2DM which is driven by reactive
oxygen species associated with multiple toxicities (table
6) [8].
T2DM is a heterogeneous, multifactorial, polygenic dis-
ease characterized by a defect in insulin's secretion (the
beta cell secretory defect) and action (insulin resistance)
which results in elevated glucose [8,12].
T2DM may be viewed as a dynamic continuum of five
stages (table 9) [12].
eNOS and eNO
Chromosome number 7 contains the vascular eNOS gene
that encodes the transcription and synthesis of the 1203
amino acid protein enzyme eNOS. eNOS is located
uniquely within caveolae of the plasma membrane which
allows the monolayer of endothelial cells to compensate
if its fellow cellmates become dysfunctional in order to
maintain eNO production.
Once conceptualized, that a specific and unique gene
(eNOS, iNOS, nNOS) encodes the transcription of NO in
a specific organ system, the opposing faces of this highly
specialized, small, bioactive, and readily diffusible gas NO
can be better understood (table 2, 3) [13].
eNO is a natural occurring, endogenous, chain breaking
antioxidant synthesized by the endothelial cell. eNO and
superoxide are related to a healthy and dysfunctional en-
dothelium, respectively [8].
                  THE HEALTHY ENDOTHELIUM IS A NET PRO-
DUCER OF ENDOTHELIAL NITRIC OXIDE [eNO].                
Table 5: eNOS reaction the three critical arms
IF THE eNOS REACTION IS UNCOUPLED: THEN THE REACTION 
IS:
(L-arginine is not converted to NO and L-citrulline).
TREATMENT PARADIGM:
(1) Prevent competitive inhibition by ADMA (Reduce substrates: 
LDL-C, Triglycerides, Homocysteine, and Glucotoxicity formation. 
Prevent L-arginine from being converted to nitroarginine by 
nitrosylation. Reducing Redox Stress – A-FLIGHT toxicities reduc-
tion of ROS. ARGININE SUPPLEMENTATION.
(2) Prevent hs-CRP from decreasing eNOS by lowering hs-CRP and 
preventing glycation of Enos enzyme. Aggressive treatment of ele-
vated substrates.
(3) Add FOLIC ACID not only to lower Hcy and ADMA levels but 
also to restore BH2, BH3 to the active catalytic cofactor BH4. Use 
the RAAS acronym and prevent the A-FLIGHT Toxicities (ROS) 
from developing i.e. decrease the manifold toxicities of MS, IR, PD 
and overt T2DM.
BE AGGRESSIVE AND TREAT TO KNOWN GOALS:
(1) L-arginine
O2
NAD P H NAD P H Oxidase
2 e N O S
3 B H 4
() ()
()
()
→   + + () + NO L-citrulline NAD P
NAD P H NAD P  O2
O2
NAD P H Oxidase ()→  () ++ () ’
Table 6: The manifold toxicities of insulin resistance, metabolic 
syndrome and T2DM.
A-FLIGHT toxicities
A Amylin (hyperamylinemia)/amyloid toxicity ROS
Ang II (also induces PKC) ROS
AGEs/AFEs (advanced Glycosylation / fructosylation 
products)
ROS
Antioxidant reserve compromised ROS
Absence of antioxidant network ROS
Ageing ROS
Angiogenesis (induced redox stress) Arteriogenesis 
(impaired PAI-1)
ROS
Atherosclerosis – Atheroscleropathy. [ROS beget 
ROS ]
ROS
F Free fatty acid toxicity ROS
L Lipotoxicity ROS
I Insulin toxicity (hyperinsulinemia-hyperproinsuline-
mia) (endogenous)
ROS
Inflammation toxicity ROS
G Glucotoxicity (compounds peripheral insulin resist-
ance) reductive stress
ROS 
plus
Sorbitol / 'olyol pathway PKC
Pseudohypoxia (NADH/NAD increased)
H Hypertension toxicity ROS
t homocysteine toxicity ROS
T Triglyceride toxicity ROS
See reference [8,9]Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/2
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                  THE ACTIVATED, DYSFUNCTIONAL EN-
DOTHELIUM IS A NET PRODUCER OF SUPEROXIDE
[O2'] ASSOCIATED WITH T2DM AND ATHEROSCLE-
ROPATHY                
There are at least three arms in the eNOS reaction capable
of producing endothelial cell dysfunction with resultant
redox stress to the intima and islet resulting in atheroscle-
ropathy and a progressive decline in beta cell function
within the vulnerable islet.
Presentation of the hypothesis
Is type 2 diabetes mellitus a vascular disease (athero-
scleropathy) with hyperglycemia a late manifestation?
The role of NOS, NO, and redox stress.
Testing of the hypothesis
The following eNOS reaction demonstrates the location
of the vulnerable three arms of the eNOS reaction respon-
sible for the generation of eNO.
            IF THE eNOS REACTION IS UNCOUPLED: THEN
THE REACTION IS:          
L-arginine is uncoupled and not converted to NO and L-
citrulline (figure 1) (tables 3,4).
THE L-ARGININE ARM
The substrate L-arginine is an essential amino acid and is
usually not thought to be rate limiting (with the exception
of high demands in a dysfunctional endothelial state such
as atherosclerosis or the atheroscleropathy associated with
T2DM).
Arginine deficiency is a rare occurrence, however, there
can be competitive inhibition by the endogenously
produced asymmetrical dimethylarginine (ADMA) and
nitroarginine. ADMA is emerging as an important cause of
endothelial cell dysfunction.
It is an endogenously produced competive inhibitor of L-
arginine which results in a relative deficiency of the natu-
ral substrate for the eNOS enzyme to produce eNO.
ADMA accumulates by either a process of increased syn-
thesis by the protein arginine N-methyltransferases
(PRMTs) or decreased elimination by the enzyme dimeth-
ylarginine dimethylaminohydrolose (DDAH) [14–17].
DDAH selectively hydrolyzes ADMA to L-citrulline and
dimethylamine, so that the higher the DDAH activity, the
lower the ADMA levels. Importantly, inhibition of DDAH
activity results in increased ADMA levels. Both native and
oxidized LDL-cholesterol have been shown to up-regulate
PRMT while causing a decrease in the activity of DDAH
[18]. This results in an elevation of ADMA levels contrib-
uting to endothelial cell dysfunction and increased oxida-
tive stress to the intima with subsequent accelerated
atherosclerosis.
There are multiple causes for the elevation in ADMA levels
(figure 2). Each of these toxicities relate to the A-FLIGHT
acronym responsible for the production of ROS (table 6).
Recently, Faldetta CM, Laurenti O, and Desideri G [19]
were able to demonstrate in both normal human subjects
and T2DM human patients that acute L-arginine infusion
decreased plasma total homocysteine concentrations,
counteract oxidative stress, and increased the availability
of nitric oxide.
In summary, the relative deficiency of L-arginine due to el-
evation of ADMA levels contribute to oxidative stress and
result in the atheroscleropathy associated with insulin re-
sistance, metabolic syndrome, prediabetes, and overt
T2DM.
(1) L-arginine
O2
NAD P H NAD P H Oxidase
2 e N O S
3 B H 4
() ()
()
()
→   + + () + NO L-citrulline NAD P
NAD P H NAD P  O2
O2
NAD P H Oxidase ()→  () ++ () ’
Figure 1
Oxygen reacts with the eNOS enzyme in which the BH4 
cofactor has coupled NAD(P)H with L-arginine to be con-
verted to NO and L-citrulline. When uncoupling occurs the 
NAD(P)H reacts with O2 and the endothelial cell becomes a 
net producer of superoxide (O2').
NAD(P)H
NADP +
eNOS (1203 am acids) C terminal
Reductase domain N terminal
Oxidase domain
FAD FMN
Cofactor
BH4
Ca++
Fe++ Haem
e’ e’
L-arginine NO   + L-citrulline
NO
UNCOUPLING
[ O2’ ]
ENDOTHELIAL       CELL
Diabetes: A  net producer of [O2’]   
Due to uncoupling of eNOS enzyme.
Couples with NAD(P)H
L-arginine.Cardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/2
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THE eNOS ARM
Important agonists for the activation of the eNOS enzyme
(table 7) play an important role in the production of eNO.
If there is a complete loss of eNOS enzyme as in the eNOS
-/- knockout mouse model of Duplain and Sherrer [20]
insulin resistance, hypertension, and hyperlipidemia de-
velop. Their findings indicate that eNOS plays a major
role in the regulation of insulin sensitivity. To have an ef-
fect on atheroscleropathy and T2DM it would not require
a complete knockout of the gene but just one or two
changes in the 1203 amino acid protein structure in the
eNOS enzyme.
Such a gene polymorphism does exist and may become a
major player in the polygenic causes of T2DM and
atheroscleropathy:
Glu298 → Asp Gene Polymorphism (Glu298 → Asp GP)
eNOS may be impaired by abnormal structure and or
function that occurs in gene polymorphisms.
One of the first significant eNOS gene polymorphisms de-
scribed to date is Glu 298 → Asp. This amino acid substi-
tution is responsible for a statistically significant increased
frequency of hypertension and spastic angina [21]. Also,
described in a different set of patients is the occurrence of
increased abnormal coronary angiographic findings of
atherosclerosis and an association of increased events
[22–24].
The Glu298 → Asp GP is responsible for a decrease in ba-
sal NO production in healthy subjects according to the
publication by Veldman BA et al [25].
This gene polymorphism then could interact with other
gene polymorphisms and especially environmental con-
ditions such as smoking, obesity, and the A-FLIGHT toxic-
ities of IR, MS, PD, and overt T2DM. Or as in the
hypothesis, could be responsible for the development of
IR and MS which then would progress to PD or overt
T2DM. We now have a Japanese population, a UK popu-
lation, and an Italian population that correlates Glu298
→ Asp GP to atherosclerosis and CAD events [23–25].
These findings indicate that the eNOS gene is important
to the development of accelerated atherosclerosis →
atheroscleropathy. Furthermore, these three distinct pa-
tient populations indicate that this gene polymorphism is
widely distributed throughout diverse patient popula-
tions and according to Veldman [25] is present in approx-
imately 10 % of patient populations.
Recently, Noiri E and colleagues have shown that there is
a significant association of the Glu298 → Asp GP and end
stage renal disease in T2DM which once again points to
the importance of the endothelial cell and the eNOS reac-
tion [26].
Since eNOS contains 1203 amino acids there is the possi-
bility of other gene polymorphisms within the eNOS en-
zyme that have not been identified at this time.
Additionally, this gene polymorphism could interact with
other gene polymorphisms of other endogenous antioxi-
dant enzymes in the T2DM patient as we know their anti-
oxidant reserve is compromised (tables 6,8) [7,8,12].
Figure 2
The multiple stressors causing uncoupling of the eNOS 
enzyme by decreased DDAH and the increased endogenous 
inhibitor of eNOS: ADMA.
Table 7: eNOS AGONISTS
1. Bradykinin (BK).
2. Phosphorylation by PK-B also called Akt.
3. Mechanical forces – Sheer stress.
4. Acetylcholine (muscarinic receptors).
5. ADP – ATP (purinergic receptors).
6. Vascular Endothelial Cell Growth Factor (VEGF).
7. Histamine.
8. HSP – 90.
9. Acetylation by myristate (N-terminal) by palimitate (cys15 – cys26) 
Stimulated by BK.
ADMA
ROS
O2’
H2O2
A -FLIGHT
Homocysteine
RAAS
Ang II
Endothelin
HTN
GLUCOSE
T2DM
Metabolic Syndrome
Insulin Resistance
Prediabetes
Increased O2’
Decreased NO
ROS
Beget
ROS
Increased Matrix
Remodeling
LIPIDS
Endothelial Dysfunction
Uncoupling of the eNOS enzyme by increased ADMA mechanisms
Uncoupling eNOSCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/2
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As the human genome unfolds there may be other related
important gene polymorphisms identified.
The BH4 ARM
Tetrahydrobiopterin (BH4) is the necessary cofactor for
coupling L-arginine to the NAD(P)H oxidase enzyme in
order for L-arginine to be oxidized to NO and L-citrulline.
The importance of this cofactor and its mechanism is just
starting to emerge.
If this cofactor is not functioning properly the entire
eNOS reaction uncouples and the endothelium becomes
a net producer of superoxide [O2'] through the uncoupled
NAD(P)H oxidase reaction. In addition to BH4 being the
necessary cofactor it also serves as a naturally occurring
antioxidant capable of scavenging ROS such as superoxide
O2' and perioxynitrite [ONOO']. If BH4 is deficient in
supply or function the eNOS reaction not only is capable
of uncoupling with subsequent excess [O2'] and
[ONOO'] but also is at a disadvantage in that there would
be less BH4 to scavenge these local occurring reactive ox-
ygen species being produced in excess amounts [27].
It is important to note that a direct effect of folic acid is to
keep this important cofactor BH4 intact so that it can
maintain coupling of the eNOS reaction.
Table 8: Antioxidants: catalytic/enzymatic inactivation of free 
radicals.
Enzymatic antioxidants
SUPER OXIDE DISMUTASE (SOD)– Location: mitochondrion
[O2
- + SOD → H2O2 + O2]
ecSOD (extracellular)
MnSOD (mitochondrial)
CuZnSOD (intracellular)
CATALASE– Location: peroxisome
[2H2O2 + catalase → 2 H2O + O2]
GLUTATHIONE PEROXIDASE– Location: mitochondrion/
cytosol
(Glutamyl-cysteinyl-glycine tripeptide) glutathione reduced -SH to the 
oxidized disulfide GSSG.
(Glutathione peroxidase) [GSH + 2H2O2 → GSSG + H2O + O2]
(Glutathione reductase) [GSSG → GSH] at the expense of [NADH → 
NAD+] and/or [NAD(P)H → NAD(P)+]
*NOS (nitric oxide synthase). – Location: membrane
Isoforms:
(e) NOS (endothelial): good (importance of eNOS uncou-
pling) LDL native and oxidized.
(n) NOS (neuronal): good
(i) NOS (inducible-inflammatory): GOOD in host defense. BAD in 
chronic inflammation, ischemia – ischemia reperfusion 
injury, acute and chronic as in autoimmunity – T1DM.
O2
- and nitric oxide (NO) are consumed in this process with the cre-
ation of reactive nitrogen species (RNS).
O2
- + NO → ONOO- (peroxynitrite) + tyrosine → nitrotyrosine. 
(also causes eNOS uncoupling)
Nitrotyrosine reflects redox stress and leaves a measurable footprint.
NO: the good; O2
-: the bad; ONOO-: the ugly [122]
eNO : A chain breaking antioxidant see (table 2) item 6.
eNOS uncoupling causes the generation of O2' instead of 
NO induced by LDL-C, Glucose, O2', and ONOO'.
Nonenzymatic antioxidants
URIC ACID
VITAMIN A, VITAMIN C, VITAMIN E
THIOLS
APOPROTEINS: Ceruloplasmin and transferrin. Bind copper and iron 
in forms which cannot participate in the Fenton reaction. [7,8,12]
Table 9: The five stages of T2DM: the natural progressive history 
of T2DM.
I. LATENT STAGE:[EARLY]
Insulin Resistance:
*Genetic Component.
*Environmental Component. [Modifiable] Obesity / Sedentary life 
style. [Nonmodifiable] Ageing.
Beta Cell Defect: (Dysfunction)
*Genetic....... Abnormal processing, storage, or secretion.
*Intracellular extracellular amylin fibril toxicity. Abnormal process-
ing, storage, or secretion.
Intra-Islet Endothelial Absorptive Defect:
*Heparan sulfate proteoglycan (HSPG) PERLECAN of the capillary 
endothelial cells avidly attracts amylin (IAPP) and islet amyloid 
forms an envelope around the capillary. This is in addition to the 
increase in basement membrane associated with the pseudohy-
poxia (associated with glucotoxicity) and the redox stress within 
the capillary.
II. TRANSITION STAGE: [MIDDLE]
PERSISTENT HYPERINSULINEMIA
PERSISTENT HYPERAMYLINEMIA – Continued remodeling of 
endocrine pancreas. (AMYLOID) Beta cell displacement, dysfunc-
tion, mass reduction, and diffusion barrier.
III. IGT STAGE: *"Pre-diabetes" HHS ADA term (Impaired 
Glucose Tolerance)
[LATE] *[Start treatment at this time ] [Diagnose earlier: 
Rejuvenation of the 2 hour glucose tolerance blood sugar 
140–199 mg.]
*Increased insulin resistance [Feeds forward] > Glucotoxicity 
[Feeds forward] > Insulin resistance [Feeds forward] > Glucotox-
icity : creating a vicious cycle.
*Islet amyloid. Increasing beta cell defect. Loss of beta cell mass 
with displacement. [Remodeling of islet architecture including 
ECM] Beta cell loss centrally.
IV. IFG STAGE: *"Pre-diabetes" HHS ADA term (Impaired 
Fasting Glucose)
[LATER] Blood sugar > 110 mg./dl. < 126 mg./dl.
[Impaired Hepatic Glucose Production (HGP)]. Increasing global insu-
lin resistance (HEPATIC) with subsequent gluconeogenesis. Feeding 
forward in the vicious cycle to accelerate insulin resistance globally
V. OVERT STAGE: [TOO LATE] 50% loss of Beta Cell 
Function.
Va. Vb. Vc. Phases I, II, III Mild / Moderate / Severe / Com-
plete. Use medications that do not increase insulin or AMYLIN. Use 
combination therapy. Start treatment at stage III-IV (IGT) 
(IFG)
*Paradigm Shift. Start treatment at the earlier stage of IGTCardiovascular Diabetology 2003, 2 http://www.cardiab.com/content/2/1/2
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The lowering of homocysteine is an indirect effect of folic
acid aiding in the decreased production of ADMA due to
the effect of Hcy on DDAH. Folic acid given to patients
with T2DM have an improvement of endothelial relaxa-
tion before Hcy has time to be lowered. It works almost
immediately before the Hcy is lowered [28,29].
When you look at the three arms of importance for the
eNOS reaction there are two possible changes in the treat-
ment paradigm (in addition to lowering the substrates of
the A-FLIGHT toxicities (table 6) and the RAAS acronym
[8]) for these patients who suffer from endothelial dys-
function associated with atheroscleropathy, IR, MS, PD,
and T2DM.
First, we need to take a global risk reduction approach (by
treating each risk factor in the A-FLIGHT toxicities acro-
nym in order to decrease the clinical substrates of lipids,
hypertension, and glucotoxicity without elevating endog-
enous insulin or amylin) in order to decrease the progres-
sion of the disease. Second, we should now include in the
treatment paradigm the use of folic acid and arginine sup-
plementation. T2DM is now considered to be a coronary
risk equivalent and therefore all patients with T2DM
should be on folate supplementation, as well as, the non-
diabetic atherosclerotic patient.
Those patients with persistent endothelial cell dysfunc-
tion after the standard goals have been reached should
consider arginine supplementation and possibly should
be considered even sooner in the treatment paradigm if
there is a history or evidence of symptomatic peripheral
arterial disease, congestive heart failure and / or diastolic
dysfunction [17,30,31].
Folic acid – 5MTHF
This water soluble B vitamin has been recently gaining
considerable attention due to its positive role in cardio-
vascular disease, neurodegenerative disorders, neural tube
defects, and cancer. Folic acid plays an important role in
the remethylation of homocysteine and is thus capable of
lowering elevated levels of homocysteine (figure 3) [32].
Deficiency or impairment of folate metabolism is associ-
ated with hyperhomocysteinemia (hHcy), hypomethyla-
tion (the decreased one carbon unit transfer to purines
and pyrimidines for DNA repair and biosynthesis), DNA
damage, and impaired cell proliferation, malignancies,
and impaired eNO production [33–37]. 5-MTHF is an
electron donor, a hydrogen donor, and a methyl donor.
Each of these attributes confers a unique role to its func-
tion. In regards to the eNOS reaction it supplies both hy-
drogen and electrons to BH2 and BH3 to restore BH4 (the
necessary cofactor for the eNOS reaction). This attribute
allows the eNOS reaction to re-couple and restores the
capability of this reaction to be once again a net producer
of eNO and restores endothelial dependent vasodilata-
tion in T2DM and hyperlipidemia [38]. Recently, the
combination of folic acid, vitamin B12, and vitamin B6
was able to demonstrate a reduction of in-stent restenosis
and recurrent events in up to one year follow up in the
Swiss heart study [39–41].
The eNOS hypothesis
            Is T2DM a vascular disease with a dysfunctional
eNOS enzyme reaction, resulting in endothelial cell
dysfunction and associated diminished eNO production?
Is atheroscleropathy an early manifestation and hypergly-
cemia a later manifestation?          
The following quote is pertinent to this discussion.
Figure 3
Hcy (demethylated Methionine) can enter the remethylation 
cycle with the aid of Folic Acid (5-Methyl-tetrahydrofolate) 
and the Folate cycle, the enzyme Methionine Synthase, and 
the necessary Cofactor B12. Folic Acid in addition to being a 
methyl-donor can serve as an electron or hydrogen donor to 
restore the required BH4 Cofactor to recouple the eNOS 
enzyme necessary for the production of eNO from L-
arginine. Hcy may also enter the Transsulfuration Pathway 
with the assistance of Cystathionine Beta Synthase (CBS) 
enzyme and the necessary Cofactor B6 to form Cystathio-
nine and Cysteine which can then be excreted in the urine or 
converted to the very important antioxidant Glutathione. 
The substrate Folic Acid and the Cofactors B6 and B12 are 
very important not only for improving hyperhomocysteine-
mia but also important for the recoupling of the BH4 cofac-
tor to the eNOS enzyme for the production of eNO.
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"Diabetes must take its place alongside the other major
risk factors as important causes of cardiovascular disease.
In fact, from the point of view of cardiovascular medicine,
it may be appropriate to say: "diabetes is a cardiovascular
disease" [42].
Implications of the hypothesis
Could it be that one of the polygenic causes of T2DM in-
volve the eNOS enzyme? Such as one or more gene poly-
morphisms resulting in a defective but functioning eNOS
enzyme. This would certainly help to explain the earlier
discussed atheroscleropathy associated with T2DM.
This gene polymorphism could interact with the environ-
ment to produce an even more defective eNOS enzyme
with increasing endothelial cell dysfunction. Smoking,
obesity, hyperlipidemia, hypertension, sedentary life style
are all known risk factors and all too often they cluster cre-
ating the metabolic syndrome with a markedly elevated
tension of redox stress not only in the islet but also within
the intima of the arterial vessel wall. A single amino acid
substitution in the primary structure could have a consid-
erable effect on the structure and function of this omnip-
otent enzyme and its reaction producing eNO.
Here is an example where a defective gene could be made
much more impotent if there were additional stresses
placed on it through a stressor molecule such as ADMA.
This endogenously produced competitive inhibitor of L-
arginine (as well as an endogenous inhibitor of the eNOS
reaction) would cause the eNOS reaction to uncouple and
become a net producer of superoxide even before the glu-
cose becomes elevated, thus stressing the islet and the in-
tima before hyperglycemia is detected. This is why we
should consider stress testing (by utilizing the 75 gram
oral 2 hour post prandial glucose tolerance test) the pa-
tient in order to detect impaired glucose tolerance (stage
III table 9) in order to reduce the oxidative and
postprandial reductive stress to these organs in order to
spare them from the devastating natural progressive histo-
ry of T2DM and atheroscleropathy. Exercise induced skel-
etal muscle glucose transport (GLUT 4) is eNOS
dependent [43–45]. If the production of eNO were defec-
tive due to gene polymorphism and environmental inter-
action there would be increasing peripheral insulin
resistance. This is just what Duplain and Scherrer were
able to demonstrate in their eNOS -/- model: Insulin re-
sistance, hypertension, and hyperlipidemia.
In humans with gene polymorphism the eNOS enzyme
may be capable to withstand the many years of redox
stress before the defect in eNOS becomes evident. Howev-
er, if the stressors were of sufficient magnitude such as
seen in the adolescent youth with sedentary life style plus
high carbohydrate, high fat western diet (over nutrition)
the manifestation of type 2 diabetes may become evident
before the youth has reached the more normal middle age
in life. This is just what we are experiencing in the USA.
Not only are the adolescent youth developing T2DM at an
alarming rate, but also, the age of onset of T2DM in adults
is becoming younger and younger. It is entirely possible
that these abnormal gene polymorphisms could be very
old and have never caused a problem until there was suf-
ficient changes in the environment (the thrifty gene hy-
pothesis: gene – environmental interaction).
Peripheral insulin resistance would certainly place an
undo burden on the pancreas with elevated levels of en-
dogenous insulin and amylin with a chronically activated
RAAS at the local organ-tissue levels.
The additional heightened redox stress and the A-FLIGHT
toxicities associated with insulin resistance and metabolic
syndrome would only aggravate the underlying eNOS
polymorphisms by placing an undo burden on the islet
and the intima.
Conclusion
"YOU CAN'T SEE THE FOREST FOR THE TREES"
If we approach T2DM as initially being a vascular disease
for many years with glucotoxicity being a later manifesta-
tion, then as clinicians and researchers we may be more
likely to view this disease in a global perspective.
The Steno-2 study by Gaede P et al. [46,47] just published,
revealed a significant reduction in cardiovascular and mi-
crovascular events of nearly 50%. Their intensified inter-
vention against multiple risk factors in patients with type
2 diabetes was quite impressive.
Therefore, in T2DM we should consider looking at the
multiple toxicities and how they interact with each other
to form "the whole disease" and return metabolic and re-
dox homeostasis to the organism.
"We must protect the forests (the whole disease) for our
children, grandchildren and children yet to be born. We
must protect the forests for those who can't speak for
themselves such as the birds, animals, fish and trees (and
our patients)." --- Chief Edward Moody, Qwatsinas, Nux-
alk Nation.
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